Effect of Thromboxane A2 Antagonist GR32191B on Prostanoid and Nonprostanoid Receptors in the Human Internal Mammary Artery
GW HE,CQ YANG
DOI: https://doi.org/10.1097/00005344-199507000-00003
IF: 3.271
1995-01-01
Journal of Cardiovascular Pharmacology
Abstract:Summary: Arterial grafts have been demonstrated to be very effective for coronary artery bypass surgery. Thromboxane A2 (TXA2) is a potent vasoconstrictor for arterial grafts. To determine whether the specific TXA2 (TP) receptor antagonist GR32191B is effective in inhibition of prostanoid or nonprostanoid receptors, we studied the effect of GR32191B in human internal mammary artery (IMA) segments, taken from coronary bypass patients, in organ chambers. In IMA precontracted with U46619 (10 nM, n = 7), prostaglandin F2α (PGF2α 1 μM, n = 7), or potassium chloride (K+ 25 μM, n = 6). GR32191B induced 100.0 ± 0, 97.86 ± 2.14, or 45.87 ± 7.63% relaxation. In other experiments, one IMA ring taken from each patient was used as a control and others from the same patient were allocated to other groups treated with different concentrations of GR32191B [3–300 nM for U46619, 30 nM-3 μM for PGF2α, 300 nM-100 μM for K+, 3μM norepinephrine (NE), and 3μM for 5-hydroxy-tryptamine (5-HT)] for 1 h before concentration-contraction curves to these vasoconstrictors (expressed as percentage of K+-induced contraction force) were established. Treatment with GR32191B (300 nM) significantly decreased the contraction induced by U46619 (from 306.4 ± 22.1 to 61.9 ± 24.9%, p < 0.01) and that induced by PGF2α (from 208.2 ± 13.5 to 1.4 ± 1.4%, p < 0.0001). However, higher concentrations of GR32191B did not significantly inhibit the contraction induced by NE (from 135.0 ± 20.0 to 89.0 ± 30.4%, p > 0.05), 5-HT (from 149.4 ± 27.4 to 118.8 ± 30.8%, p > 0.05), or K+ (from 185.7 ± 23.9 to 152.7 ± 22.8%, p > 0.05). Our results suggest that GR32191B is a highly potent and specific TXA2 receptor antagonist for the human IMA. These findings may have important clinical implications in coronary artery bypass grafting surgery.